Abstract
The transfer of lead molecules from discovery into process development at a relatively fast pace requires a process of candidate selection that assesses if a candidate is not only active and safe but also “manufacturable.” Formulation and process stability of potential candidates help narrow down lead candidates at an early stage, prior to large-scale manufacturing, by a process of rank-ordering properties generated from process and long-term stability studies. Such an assessment of the molecules’ manufacturability is especially useful when binding affinity and bioactivity are comparable among the various candidates under question. This chapter reviews several case studies that explore the utility of early-stage molecule or manufacturability assessments in moving forward therapeutic candidate/s by finely balancing potency and pharmacokinetics with the manufacturing capability of the candidate/s under question.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Badmington F, Wilkins R, Payne M, Honig ES (1995) Vmax testing for practical microfiltration train scale-up in biopharmaceutical processing. Pharm Technol 19:64–76
Cromwell MEM, Hilario E, Jacobson F (2006) Protein aggregation and bio-processing. AAPS J 8:E572–E579
Grillo AO (2010) Late-state formulation development and characterization of biopharmaceuticals. In: Jameel F, Hershenson S (eds) Formulation and process development strategies for manufacturing biopharmaceuticals. Wiley, Hoboken, NJ, pp 161–171
Jameel F, Padala C, Rathore N, Gupta K, Sethuraman A (2010) Impact of uncontrolled vs. controlled rate freeze thaw technologies on process performance and product quality. PDA J Pharm Sci and Technol 64(4):290–298
Jiang Y, Ramachander R, Wen J, Li C, Li J, Angell N, Bondarenko P, Narhi L (2008) Manufacturability assessment for a successful therapeutic product. 236th ACS National Meeting, Division of Biochemical Technology, BIOT110, Philadelphia, PA, p 49
Kiese S, Papppenberger A, Friess W, Mahler HC (2008) Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci 97(10):4347–4366
Kolhe P, Holding E, Lary A, Chico S, Singh SK (2009) Large scale freezing of biologics: understanding protein and solute concentration changes in a cryovessel—part I. BioPharm Int 23(6):53–60
Lashmar UT, Vnanderburgh M, Little SJ (2007) Bulk freeze-thaw of macromolecules—effect of cryoconcentration on their formulation and stability. BioProcess Int 5(6):44–54
Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I et al (2010) Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs 21:907–916
Narhi LO, Jiang Y, Deshpande R, Kang S, Shultz J (2010) Approaches to control protein aggregation during bulk production. In: Wang W, Roberts CJ (eds) Aggregation of therapeutic proteins. Wiley, Hoboken, NJ, pp 257–299
Nayak A, Coladene J, Bradford V, Perkins M (2011) Characterization of subvisible particle formation during the filling pump operation of a monoclonal antibody solution. J Pharm Sci 100(10): 4198–4204
Ramachander R (2008) Manufacturability assessments for early stage therapeutic candidate screenings. Presented at the IBC BPI Meeting, Anaheim, CA
Rathore N, Rajan R (2008) Current perspectives on stability of drug products during formulation, fill and finish operations. Biotechnol Prog 24:504–514
Rathore AS, Winkle H (2009) Quality by design for biopharmaceuticals. Nat Biotechnol 27:26–34
Rehder DS, Chelius D, McAuley A, Dillon TM, Xiao G, Crouse-Zeineddini J, Vardanyan L, Perico N, Mukku V, Brems DN, Matsumura M, Bondarenko PV (2008) Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. Biochemistry 47(8):2518–2530
Singh SK, Kolhe P, Wang W, Nema S (2009) Large-scale freezing of biologics: a practitioner’s review, part 1: fundamental aspects. BioProcess Int 7(9):32–44
Yadav S, Sreedhara A, Kanai S, Liu J, Lien S, Lowman H, Kalonia DS, Shire SJ (2011) Establishing a link between amino acid sequences and self-associating and viscoelastic behavior of two closely related monoclonal antibodies. Pharm Res 28(7):1750–1764, Epub 2011 Apr 6
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Ramachander, R., Rathore, N. (2013). Molecule and Manufacturability Assessment Leading to Robust Commercial Formulation for Therapeutic Proteins. In: Kolhe, P., Shah, M., Rathore, N. (eds) Sterile Product Development. AAPS Advances in the Pharmaceutical Sciences Series, vol 6. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7978-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7978-9_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7977-2
Online ISBN: 978-1-4614-7978-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)